Anti-tumour Potential of Punica granatum (Pomegranate) Seed in Testosterone-induced Benign Prostate Hyperplastic Wistar Albino Rats
Asian Journal of Research and Reports in Urology,
Aim: The aim of this study was to assess the anti-tumour potentials of Punica granatum (Pomegranate) seed in testosterone-induced Benign Prostate Hyperplastic Wistar albino Rats.
Study Design: This study is an experimental study.
Place and Duration of Study: The experimental aspect of this study was conducted at the animal house, Department of Pharmacology, University of Port Harcourt between April and September, 2019.
Methodology: Seventy (70) adult albino Wistar rats were used for this study. They were divided into 12 groups of 5 rats each (apart from normal control, BPH and PC control groups that contained 10 rats each) that were further divided into 5 rats for each group and fed with commercial rat diet and clean drinking water ad libitum. Aqueous and ethanol extracts of Punica granatum seed were prepared using the maceration method. Benign Prostate Hyperplasia was induced in rats after they submitted to bilateral orchiectomy by daily injections of testosterone propionate (TP) (4 mg/kg b.wt.sc). Rats were treated with 500 or 1500 mg/kg b.wt. of aqueous or ethanoI extracts of Punica granatum seed, dutasteride or in combination. Administration of extracts was done by gavage. At the end of 30 days, the rats were anaesthetized with chloroform and blood samples were collected into lithium heparin bottles through cardiac puncture and serum prostate specific antigen (PSA) was analyzed using rat specific ELISA kits for PSA. The prostate gland was excised, washed, weighed and length, breath and width were measured. The organs were later preserved in formalin for histological analysis. Statistical analysis was done using statistical package for social sciences (SPSS) version 22.0 and P values less than .05 were considered significant.
Results: The results showed that subcutaneous administration of 4mg/kg of testosterone propionate caused a significant increase in prostrate weight (from 216.2 ± 10.5 to 635 ± 78.8 mg), prostate volume (from 0.83 ± 0.11cm3 to 0.23 ± 0.05 cm3) and prostate specific antigen (from 76.34 ± 3.55 to 716 ± 56.1 pg/ml) at p<.05. However, when the rats were treated with both aqueous and ethanol extracts of Punica granatum seed, in combination with dutasteride and when simultaneously administered with testosterone, the above stated parameters were observed to have significantly decreased. Moreover, histological findings for rat prostates corroborated with the biochemical findings.
Conclusion: From our findings of the biochemical and histological changes in rats, BPH was induced in castrated male rats after the subcutaneous injection of 4mg/kg b.wt. testosterone propionate. It was also observed that extracts of Punica granatum seed administered orally ameliorated BPH in rats, by decreasing prostate size and weight, prostate index and prostate specific antigen levels in treated rat groups compared with the BPH model group. Both doses of the two plant extracts individually and in combination with dutasteride also markedly reduced prostate parameters.
- Punica granatum (pomegranate) seed
- benign prostate hyperplastic albino wistar rats.
How to Cite
O’Leary MP. Lower urinary tract symptoms/benign prostatic hyperplasia: Maintaining symptom control and reducing complications. Urology. 2003;62(3):15– 23.
Ho CK, Habib FK. Estrogen and androgen signaling in the pathogenesis of BPH. National Review of Urology. 2011;8:29 41.
Huggins C, Hodges CV. Studies on prostatic cancer. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Journal of Urolology. 2002;168:9 12.
Gupta A, Gupta S, Pavuk M, Roehrborn CG. Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. Urology. 2006;68:1198–205.
Sarma AV, Parsons JK, McVary K, Wei JT. Diabetes and benign prostatic hyperplasia/lower urinary tract symptoms—what do we know? Journal of Urology. 2009;182:32–7.
Shoskes DA. Phytotherapy in chronic prostatitis. Urology. 2002;60(6):35 7.
Hirsch IH. Integrative urology: A spectrum of complementary and alternative therapy. Urology. 2000;56:185 9.
Newton P. The use of medicinal plants by primates: amissing link? Trends in Ecological Evolution. 1991;6:297–9.
Sahebkar A, Ferri C, Giorgini P. Effects of pomegranate juice on blood pressure: A systematic review and meta-analysis of randomized controlled trials. Pharmacology Research. 2017;115:149-61.
Demin, G. & Yingying, Z. Comparative antibacterial activities of crude polysaccharides and flavonoids from Zingiber officinale and their extraction. American Journal of Tropical Medicine. 2010;5:235–8.
Khwairakpam AD, Bordoloi D, Thakur KK. Possible use of Punica granatum (Pomegranate) in cancer therapy. Pharmacological Research. 2018;133:53-64.
Wang L, Martins-Green M. Pomegranate and its components as alternative treatment for prostate cancer. International Journal of Molecular Science. 2014; 15(9):14949-66.
Cheng X, Yao X, Xu S. Punicalagin induces senescent growth arrest in human papillary thyroid carcinoma BCPAP cells via NF-kappaB signaling pathway. Biomedicine and Pharmacotherapy. 2018;103:490-8.
National Institute of Health. Guide for the Care and Use of Laboratory Animals prepared by the National Institute of Health; 1985.
Center for Drug Evaluation and Research. U.S. Department of Health and Human Services Food and Drug Administration: Conversion of Human and Animal doses for chemical used for pre-clinical studies; 2005.
Obisike UA, Nwachuku EO, Boisa N, Nduka N. Determination of exogenous testosterone propionate dose for induction of benign prostatic hyperplasia in rat model. European Journal of Biomedical and Pharmaceutical Sciences. 2019;6(13): 141-47.
Van Coppenolle F, Le Bourhis X, Carpentier F, Delaby G, Cousse H, Raynaud JP, Dupouy JP, Prevarskaya N. Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: Comparison with finasteride. Prostate. 2000;43(1):49-58.
Veeresh SV, Veeresh B, Anup A, Patil Y, Warke B. Lauric acid and myristic acid prevent testosterone-induced prostatic hyperplasia in rats Author links open overlay panel. European Journal of Pharmacology. 2010;626:2–3.
McCarthy U, Distaburd RT, Larry DG. Novel Estimation of Plasma Protein. Journal of Diagnostic Medicine. 1983;232: 240-3.
Karnezis AN, Cho KR, Gilks CB, Pearce CL, Huntsman DG. The disparate origins of ovarian cancers: Pathogenesis and prevention strategies. National Review of Cancer. 2017;17(1):65–74.
Adhami VM, Khan N, Mukhtar H. Cancer chemoprevention by pomegranate: Laboratory and clinical evidence. Nutrition and Cancer, 2009;61:811-5.
Kim ND, Mehta R, Yu W. Chemoprevetive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Research and Treatment. 2002;71:203-17.
Settheetham W, Ishida T. Study of genotoxic effects of antidiarrheal medicinal herbs on human cells in vitro. The Southeast Asian Journal of Tropical Medicine and Public Health. 1995;26:306–10.
Mavlyanov SM, Islambekov SY, Karimdzhanov AK, Ismailov AI. Polyphenols of pomegranate peel show marked anti-viral and anti-tumor action. Khimiia Prirodnykh Soedineni. 1997;33: 98–9.
Tsai HH, Lin HW, Pickard AS, Tsai HY, Mahady GB. Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: a systematic literature review. International Journal of Clinical Practice. 2012;66:1056-78.
McConnell K, Jo G, Lam F. Benign prostatic hyperplasia. Journal of Urology. 1992;85(5):56-9.
Ozbay T, Nahta R. Delphinidin inhibits HER2 and Erk1/2 signaling and suppresses growth of HER2-overexpressing and triple negative breast cancer cell lines. Breast Cancer. 2011;5: 143-54.
Colombel J, Buttyan O. Bilateral orchiectomy in rats. Urology. 1995;45:567-71.
Ammar A, Esmat MDH, Hassona MG, Tadros AB, Abdel-Naim H, Guns EST. The effects of pomegranate fruit extract on testosterone-induced BPH in rats. Prostate. 2015;75(7):679–92.
Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Medical and Clinical Journal of North America. 2011;95: 87 100.
Abstract View: 12 times
PDF Download: 8 times